



## Listing Compliance Reviews FY2016—17



	Random	Target	Project	Total
<b>Compliance status determined</b>				
Medicines with with no compliance breaches #	24%	6%	19%	20%
Medicines with verified compliance breaches #	76%	94%	81%	80%
Compliance status determined Sub-Total	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>
Compliance status determined of total	<b>87%</b>	<b>77%</b>	<b>72%</b>	<b>76%</b>
<b>Compliance status not determined*</b>				
Medicines cancelled by Sponsor after RFI	63%	40%	56%	56%
Medicines remain on ARTG (not manufactured)	38%	60%	43%	44%
Medicines cancelled by TGA for other reasons	0%	0%	1%	1%
Compliance status not determined Sub-Total	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>
Compliance status not determined of total	<b>13%</b>	<b>23%</b>	<b>28%</b>	<b>24%</b>

## Listing Compliance Reviews FY2015—16



	Random	Target	Project	Total
<b>Compliance status determined</b>				
Medicines with with no compliance breaches #	28%	6%	0%	20%
Medicines with verified compliance breaches #	72%	94%	100%	80%
Compliance status determined Sub-Total	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>
<b>Compliance status determined of total</b>	<b>84%</b>	<b>88%</b>	<b>94%</b>	<b>86%</b>
<b>Compliance status not determined*</b>				
Medicines cancelled by Sponsor after RFI	70%	62%	50%	68%
Medicines remain on ARTG (not manufactured)	30%	31%	50%	31%
Medicines cancelled by TGA for other reasons	0%	8%	0%	2%
Compliance status not determined Sub-Total	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>
<b>Compliance status not determined of total</b>	<b>16%</b>	<b>12%</b>	<b>6%</b>	<b>14%</b>